Richard Green Pharma Consulting Ltd 15784761 false 2025-01-01 2025-12-31 2025-12-31 The principal activity of the company is other professional, scientific and technical activities. Digita Accounts Production Advanced 6.30.9574.0 true 15784761 2025-01-01 2025-12-31 15784761 2025-12-31 15784761 bus:OrdinaryShareClass1 2025-12-31 15784761 bus:OrdinaryShareClass2 2025-12-31 15784761 bus:OrdinaryShareClass3 2025-12-31 15784761 core:RetainedEarningsAccumulatedLosses 2025-12-31 15784761 core:ShareCapital 2025-12-31 15784761 core:CurrentFinancialInstruments 2025-12-31 15784761 core:CurrentFinancialInstruments core:WithinOneYear 2025-12-31 15784761 core:OfficeEquipment 2025-12-31 15784761 bus:SmallEntities 2025-01-01 2025-12-31 15784761 bus:AuditExemptWithAccountantsReport 2025-01-01 2025-12-31 15784761 bus:FullAccounts 2025-01-01 2025-12-31 15784761 bus:SmallCompaniesRegimeForAccounts 2025-01-01 2025-12-31 15784761 bus:RegisteredOffice 2025-01-01 2025-12-31 15784761 bus:Director1 2025-01-01 2025-12-31 15784761 bus:Director2 2025-01-01 2025-12-31 15784761 bus:OrdinaryShareClass1 2025-01-01 2025-12-31 15784761 bus:OrdinaryShareClass2 2025-01-01 2025-12-31 15784761 bus:OrdinaryShareClass3 2025-01-01 2025-12-31 15784761 bus:PrivateLimitedCompanyLtd 2025-01-01 2025-12-31 15784761 core:OfficeEquipment 2025-01-01 2025-12-31 15784761 countries:UnitedKingdom 2025-01-01 2025-12-31 15784761 2024-06-17 2024-12-31 15784761 2024-12-31 15784761 bus:OrdinaryShareClass1 2024-12-31 15784761 bus:OrdinaryShareClass2 2024-12-31 15784761 bus:OrdinaryShareClass3 2024-12-31 15784761 core:RetainedEarningsAccumulatedLosses 2024-12-31 15784761 core:ShareCapital 2024-12-31 15784761 core:CurrentFinancialInstruments 2024-12-31 15784761 core:CurrentFinancialInstruments core:WithinOneYear 2024-12-31 15784761 bus:OrdinaryShareClass2 2024-06-17 2024-12-31 15784761 bus:OrdinaryShareClass3 2024-06-17 2024-12-31 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 15784761

Richard Green Pharma Consulting Ltd
Unaudited Filleted Financial Statements
for the Year Ended 31 December 2025

(filleted for filing purposes)

Richard Green Pharma Consulting Ltd

Contents

Company Information | 1
Balance Sheet | 2
Notes to the Unaudited Financial Statements | 3 to 7

Richard Green Pharma Consulting Ltd

Company Information

Directors | R D Green

Registered office | 56 Queens Road Ash Canterbury Kent CT3 2BA

Richard Green Pharma Consulting Ltd

(Registration number: 15784761)
Balance Sheet as at 31 December 2025

| Note | 2025 £ | 2024 £
Fixed assets |  |  |
Tangible assets | 4 | 1,379 | -
Current assets |  |  |
Stocks | 5 | 7,555 | -
Debtors | 6 | 360 | 2
Cash at bank and in hand |  | 23,287 | -
|  | 31,202 | 2
Creditors: Amounts falling due within one year | 7 | (7,206) | -
Net current assets |  | 23,996 | 2
Total assets less current liabilities |  | 25,375 | 2
Provisions for liabilities |  | (262) | -
Net assets |  | 25,113 | 2
Capital and reserves |  |  |
Called up share capital | 8 | 4 | 2
Retained earnings |  | 25,109 | -
Shareholders' funds |  | 25,113 | 2

For the financial year ending 31 December 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

• | The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and
• | The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the Board on 3 February 2025 and signed on its behalf by:

......................................... R D Green Director | ......................................... S H R Green Director |

Richard Green Pharma Consulting Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2025

1 | General information

The company is a private company limited by share capital, incorporated in United Kingdom.

The address of its registered office is:
56 Queens Road
Ash
Canterbury
Kent
CT3 2BA
England

These financial statements were authorised for issue by the Board on 3 February 2025.

2 | Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.
The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Foreign currency transactions and balances

Transactions in foreign currencies are initially recorded at the functional currency rate prevailing at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated into the respective functional currency of the entity at the rates prevailing on the reporting period date. Non-monetary items carried at fair value that are denominated in foreign currencies are retranslated at the rate on the date when the fair value is re-measured.
Non-monetary items measured in terms of historical cost in a foreign currency are not retranslated.

Richard Green Pharma Consulting Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2025

Tax

The tax expense for the period comprises current and deferred tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Deferred tax is recognised in respect of all timing differences between taxable profits and profits reported in the financial statements.
Unrelieved tax losses and other deferred tax assets are recognised when it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.
Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.
The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class | Depreciation method and rate
Office equipment | 15% reducing balance

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.
Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Richard Green Pharma Consulting Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2025

Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost is determined using the first-in, first-out (FIFO) method.
The cost of finished goods and work in progress comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the inventories to their present location and condition. At each reporting date, stocks are assessed for impairment. If stocks are impaired, the carrying amount is reduced to its selling price less costs to complete and sell; the impairment loss is recognised immediately in profit or loss.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.
Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Defined contribution pension obligation

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.
Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

3 | Staff numbers

The average number of persons employed by the company (including directors) during the year, was 2 (2024 - 1).

Richard Green Pharma Consulting Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2025

4 | Tangible assets

| Office equipment £ | Total £
Cost or valuation
Additions | 1,623 | 1,623
At 31 December 2025 | 1,623 | 1,623
Depreciation
Charge for the year | 244 | 244
At 31 December 2025 | 244 | 244
Carrying amount
At 31 December 2025 | 1,379 | 1,379

5 | Stocks

| 2025 £ | 2024 £
Work in progress | 7,555 | -

6 | Debtors

Current | 2025 £ | 2024 £
Prepayments | 360 | -
Other debtors | - | 2
| 360 | 2

7 | Creditors

Creditors: amounts falling due within one year

| Note | 2025 £ | 2024 £
Due within one year |  |  |
Other related parties |  | 408 | -
Other creditors |  | 6,798 | -
|  | 7,206 | -

Richard Green Pharma Consulting Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2025

8 | Share capital

Allotted, called up and fully paid shares

| 2025 | 2024
| No. | £ | No. | £
Ordinary shares of £1 each | 2 | 2 | 2 | 2
Ordinary A share of £1 (2024 - £0) each | 1 | 1 | - | -
Ordinary B share of £1 (2024 - £0) each | 1 | 1 | - | -
| 4 | 4 | 2 | 2